Deep-vein thrombosis (DVT) is a serious medical condition with minimal symptoms, yet it has never received the same attention as heart attack or stroke. The Council for Leadership On Thrombosis Awareness and Management aims to raise awareness and educate the public about DVT risk factors and symptoms.
A new study published in The Lancet reveals that pegvisomant normalized IGF-I concentrations in 97% of patients with acromegaly after 12 months of treatment. Patients experienced improved symptoms and a better quality of life, highlighting the potential benefits of this innovative drug.
The US FDA has approved Tracleer (bosentan) tablets as the first oral treatment for patients with pulmonary arterial hypertension. The medication works by blocking the effects of endothelin on blood vessels, improving exercise capacity and reducing symptoms. Regulatory reviews are ongoing in several countries.
A single dose of enoxaparin sodium has been shown to prevent the development of blood clots in high-risk patients who undergo long-haul flights. Researchers found that only one superficial clot occurred among 82 participants receiving enoxaparin, compared to 3.6% DVT rates in those taking aspirin and 4.8% in those with no treatment. Th...
Scientists have discovered a new light-activated protein in surface water bacteria, which may represent a new mechanism for cycling carbon in the oceans. The protein, called proteorhodopsin, pumps ions across the cell membrane when exposed to light, generating energy for marine microbes.